These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24959263)

  • 1. Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature.
    Xu M; Huang H; Xiong Y; Peng B; Zhou Z; Wang D; Yang X
    Oncol Lett; 2014 Jul; 8(1):291-294. PubMed ID: 24959263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report.
    Katano A; Yamashita H; Nakagawa K
    Mol Clin Oncol; 2017 Dec; 7(6):1061-1063. PubMed ID: 29285374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy].
    Egawa T; Okubo Y; Kemmochi T; Mori T; Sato S; Nishiya S; Mihara K; Ito Y; Makino H; Nagashima A
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1850-2. PubMed ID: 24393943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
    Yamashita H; Omori M; Takenaka R; Okuma K; Kobayashi R; Ohtomo K; Nakagawa K
    Radiother Oncol; 2014 Nov; 113(2):182-7. PubMed ID: 25466372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
    Jingu K; Matsushita H; Takeda K; Umezawa R; Takahashi C; Sugawara T; Kubozono M; Abe K; Tanabe T; Shirata Y; Yamamoto T; Ishikawa Y; Nemoto K
    BMC Cancer; 2012 Nov; 12():542. PubMed ID: 23171077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
    Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
    Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence.
    Liu Q; Xia Y; Chen Y; Zhang J; Deng J; Zhao K
    Radiat Oncol; 2020 Apr; 15(1):75. PubMed ID: 32268925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
    Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
    Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
    Ehara K; Tsutsumi K; Kinoshita Y; Ueno M; Mine S; Udagawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1375-8. PubMed ID: 18701852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases.
    Katano A; Yamashita H; Nakagawa K
    Mol Clin Oncol; 2017 Oct; 7(4):681-686. PubMed ID: 29046800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.